These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 19523489)
1. Development of a broad-spectrum antiviral with activity against Ebola virus. Aman MJ; Kinch MS; Warfield K; Warren T; Yunus A; Enterlein S; Stavale E; Wang P; Chang S; Tang Q; Porter K; Goldblatt M; Bavari S Antiviral Res; 2009 Sep; 83(3):245-51. PubMed ID: 19523489 [TBL] [Abstract][Full Text] [Related]
2. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. Panchal RG; Reid SP; Tran JP; Bergeron AA; Wells J; Kota KP; Aman J; Bavari S Antiviral Res; 2012 Jan; 93(1):23-9. PubMed ID: 22027648 [TBL] [Abstract][Full Text] [Related]
3. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. Gupta M; Mahanty S; Bray M; Ahmed R; Rollin PE J Virol; 2001 May; 75(10):4649-54. PubMed ID: 11312335 [TBL] [Abstract][Full Text] [Related]
4. Development of treatment strategies to combat Ebola and Marburg viruses. Paragas J; Geisbert TW Expert Rev Anti Infect Ther; 2006 Feb; 4(1):67-76. PubMed ID: 16441210 [TBL] [Abstract][Full Text] [Related]
5. Antiviral drug therapy of filovirus infections: S-adenosylhomocysteine hydrolase inhibitors inhibit Ebola virus in vitro and in a lethal mouse model. Huggins J; Zhang ZX; Bray M J Infect Dis; 1999 Feb; 179 Suppl 1():S240-7. PubMed ID: 9988190 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin. Kolokoltsov AA; Adhikary S; Garver J; Johnson L; Davey RA; Vela EM Arch Virol; 2012 Jan; 157(1):121-7. PubMed ID: 21947546 [TBL] [Abstract][Full Text] [Related]
7. Protective efficacy of neutralizing antibodies against Ebola virus infection. Takada A; Ebihara H; Jones S; Feldmann H; Kawaoka Y Vaccine; 2007 Jan; 25(6):993-9. PubMed ID: 17055127 [TBL] [Abstract][Full Text] [Related]
8. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. Jones SM; Stroher U; Fernando L; Qiu X; Alimonti J; Melito P; Bray M; Klenk HD; Feldmann H J Infect Dis; 2007 Nov; 196 Suppl 2():S404-12. PubMed ID: 17940977 [TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors of ebola virus infection. Picazo E; Giordanetto F Drug Discov Today; 2015 Feb; 20(2):277-86. PubMed ID: 25532798 [TBL] [Abstract][Full Text] [Related]
10. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Oestereich L; Lüdtke A; Wurr S; Rieger T; Muñoz-Fontela C; Günther S Antiviral Res; 2014 May; 105():17-21. PubMed ID: 24583123 [TBL] [Abstract][Full Text] [Related]
12. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. Ma J; Zhang X; Soloveva V; Warren T; Guo F; Wu S; Lu H; Guo J; Su Q; Shen H; Solon E; Comunale MA; Mehta A; Guo JT; Bavari S; Du Y; Block TM; Chang J Antiviral Res; 2018 Feb; 150():112-122. PubMed ID: 29253498 [TBL] [Abstract][Full Text] [Related]
13. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. Bray M; Davis K; Geisbert T; Schmaljohn C; Huggins J J Infect Dis; 1999 Feb; 179 Suppl 1():S248-58. PubMed ID: 9988191 [TBL] [Abstract][Full Text] [Related]
14. Development of therapeutics for treatment of Ebola virus infection. Li H; Ying T; Yu F; Lu L; Jiang S Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866 [TBL] [Abstract][Full Text] [Related]
15. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Kobinger GP; Feldmann H; Zhi Y; Schumer G; Gao G; Feldmann F; Jones S; Wilson JM Virology; 2006 Mar; 346(2):394-401. PubMed ID: 16356525 [TBL] [Abstract][Full Text] [Related]
16. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Bausch DG; Sprecher AG; Jeffs B; Boumandouki P Antiviral Res; 2008 Apr; 78(1):150-61. PubMed ID: 18336927 [TBL] [Abstract][Full Text] [Related]
17. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Smither SJ; Eastaugh LS; Steward JA; Nelson M; Lenk RP; Lever MS Antiviral Res; 2014 Apr; 104():153-5. PubMed ID: 24462697 [TBL] [Abstract][Full Text] [Related]
18. Antiviral effect of the heparan sulfate mimetic, PI-88, against dengue and encephalitic flaviviruses. Lee E; Pavy M; Young N; Freeman C; Lobigs M Antiviral Res; 2006 Jan; 69(1):31-8. PubMed ID: 16309754 [TBL] [Abstract][Full Text] [Related]
19. Antiviral activity of a small-molecule inhibitor of filovirus infection. Warren TK; Warfield KL; Wells J; Enterlein S; Smith M; Ruthel G; Yunus AS; Kinch MS; Goldblatt M; Aman MJ; Bavari S Antimicrob Agents Chemother; 2010 May; 54(5):2152-9. PubMed ID: 20211898 [TBL] [Abstract][Full Text] [Related]
20. Other viral bioweapons: Ebola and Marburg hemorrhagic fever. Salvaggio MR; Baddley JW Dermatol Clin; 2004 Jul; 22(3):291-302, vi. PubMed ID: 15207310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]